Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy
Source: OncLive, January 2024
A panel of oncology experts explores the intricate balance between maintaining quality of life and managing toxicity in adjuvant immunotherapy for melanoma.
This is a video synopsis/summary of an OncLive Insights® involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.
This segment discusses balancing quality of life and potential toxicity risks against possibility of cure with adjuvant therapy vs surgery alone for patients with lower-risk melanoma. Khushalani notes that 10% to 18% of patients have grade 3 or higher immune-related adverse events with adjuvant anti–PD-1 therapy, which is not trivial, especially in older patients with comorbidities. Such patients with minimal stage IIIA disease can often be safely observed after surgery without adjuvant treatment given good inherent outcomes.